Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Covid-19 Infection and Liver Injury: Clinical Features, Biomarkers, Potential Mechanisms, Treatment, and Management Challenges Publisher



Sivandzadeh GR1 ; Askari H1 ; Safarpour AR1 ; Ejtehadi F1 ; Raeisabdollahi E2 ; Lari AV3 ; Abazari MF4 ; Tarkesh F1 ; Lankarani KB5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, 7193635899, Iran
  2. 2. Department of Medical Sciences, Qom Medical Branch, Islamic Azad University, Qom, 1417613151, Iran
  3. 3. Department of Physiology, School of Medicine, Ahvaz Jundishapur, University of Medical Science, Ahvaz, 6135715794, Iran
  4. 4. Research Center for Clinical Virology, Tehran University of Medical Sciences, Tehran, 1417653761, Iran
  5. 5. Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, 71348-45794, Iran

Source: World Journal of Clinical Cases Published:2021


Abstract

It is hypothesized that liver impairment caused by coronavirus disease 2019 (COVID-19) infection might play a central role in severe clinical presentations. Liver injury is closely associated with severe disease and, even with antiviral drugs, have a poor prognosis in COVID-19 patients. In addition to the common hepatobiliary disorders caused by COVID-19, patients with pre-existing liver diseases demand special considerations during the current pandemic. Thus, it is vital that upon clinical presentation, patients with concurrent pre-existing liver disease associated with metabolic dysfunction and COVID-19 be managed properly to prevent liver failure. Careful monitoring and early detection of liver damage through biomarkers after hospitalization for COVID-19 is underscored in all cases, particularly in those with pre-existing metabolic liver injury. The purpose of this study was to determine most recent evidence regarding causality, potential risk factors, and challenges, therapeutic options, and management of COVID-19 infection in vulnerable patients with pre-existing liver injury. This review aims to highlight the current frontier of COVID-19 infection and liver injury and the direction of liver injury in these patients. © 2021 The Author(s). Published by Baishideng Publishing Group Inc. All Rights Reserved.
Other Related Docs
10. Pharmacological Treatments of Covid-19, Pharmacological Reports (2020)
23. A Review on Currently Available Potential Therapeutic Options for Covid-19, International Journal of General Medicine (2020)
28. Cancer Care Management During the Covid-19 Pandemic, Risk Management and Healthcare Policy (2020)
35. Review Article: Postmortem Liver Pathology Findings in Patients With Covid-19: A Systematic Review, International Journal of Medical Toxicology and Forensic Medicine (2021)
37. Host Factors: Implications in Immunopathogenesis of Covid-19, Pathology Research and Practice (2021)
42. Clinical Manifestations of Covid-19, Advances in Experimental Medicine and Biology (2021)
44. Photobiomodulation and Antiviral Photodynamic Therapy in Covid-19 Management, Advances in Experimental Medicine and Biology (2021)
46. Case Fatality Rate of Covid-19: A Systematic Review and Meta-Analysis, Journal of Preventive Medicine and Hygiene (2021)
47. Fatty Liver in Covid-19: A Risk Factor or a Common Receptor?, Archives of Iranian Medicine (2021)
49. Covid-19 Infection and Stroke Risk, Reviews in the Neurosciences (2021)